Tafenoquine, a primaquine analog in late-state development, is likely to be contraindicated in G6PD-deficient subjects, with a cutoff as yet to be determined.3 The facts that the geographical distribution of malaria and G6PD deficiency is shown to overlap and that Plasmodium-infected subjects, therefore, might be exposed to high doses of 8-aminoquinolines highlight the need to assess the status of G6DP in the population to ensure the safe use of these drugs.4,5. Here, G6PD is linked to malaria.